Covered recipient · General Payments record
PHUC D NGUYEN
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$3,474.11
- Reported across 42 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $1,753.24 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $480.74 | 4 |
| Lilly USA, LLC | $335.93 | 3 |
| ViiV Healthcare Company | $244.93 | 2 |
| Incyte Corporation | $124.98 | 1 |
| Phathom Pharmaceuticals, Inc. | $118.26 | 1 |
| Merck Sharp & Dohme Corporation | $109.60 | 1 |
| Axsome Therapeutics, Inc. | $109.01 | 1 |
| EMD Serono, Inc. | $108.54 | 1 |
| Theratechnologies Inc. | $106.70 | 1 |
| Novo Nordisk AS | $14.55 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | $109.01 | 11/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1148311342 | CMS |
| EMD Serono, Inc. | $108.54 | 05/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1120222795 | CMS |
| Gilead Sciences, Inc. | $105.27 | 02/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133745643 | CMS |
| Gilead Sciences, Inc. | $124.97 | 06/26/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133745645 | CMS |
| Gilead Sciences, Inc. | $147.90 | 08/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133745647 | CMS |
| Gilead Sciences, Inc. | $102.60 | 09/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1133745649 | CMS |
| Incyte Corporation | $124.98 | 12/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141232985 | CMS |
| Lilly USA, LLC | $117.97 | 06/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135319689 | CMS |
| Lilly USA, LLC | $117.18 | 07/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135296592 | CMS |
| Lilly USA, LLC | $100.78 | 10/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135287563 | CMS |
| Merck Sharp & Dohme LLC | $109.60 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1141776487 | CMS |
| Novo Nordisk Inc | $14.55 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097458305 | CMS |
| Phathom Pharmaceuticals, Inc. | $118.26 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1151102581 | CMS |
| Theratechnologies Inc. | $106.70 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1092907800 | CMS |
| ViiV Healthcare Company | $108.99 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1112746649 | CMS |
| ViiV Healthcare Company | $135.94 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1112765756 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.